Evercore ISI has upgraded CRISPR Therapeutics (CRSP, Financial) to Outperform, citing multiple upcoming catalysts that could drive the stock higher.
The firm is now factoring in CTX320 and CTX310 in vivo programs into its price target, assigning a 10% probability of success for CTX320 and 5% for CTX310. Data for CTX320 is expected in Q2, while CTX310 results are also anticipated later this year.
Additional key catalysts include:
Evercore also highlighted anticipated strong growth in cell collections for Casgevy, CRISPR's gene-editing therapy co-marketed with Vertex Pharmaceuticals (VRTX, Financial).
Reflecting these potential tailwinds, Evercore raised its price target on CRSP to $99 from $60.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。